Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Determinants of Response to Anti CD-19 CAR-T Cells for Diffuse Large B-Cell Lymphoma in Pre-Treatment Peripheral Blood Mononuclear Cells Using Single-Cell RNA-Seq

Ron Ram, Yonatan Katzenelenbogen, Anna Gurevich Shapiro, Eitan Winter, Oren Barboy, Mor Zada, Shahar Halevi, Eyal David, Irit Avivi Mazza, Ido Amit

Blood (2023) 142 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2023-190639

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Gil Fridberg, Odelia Amit, Liat Shargian, Ofrat Beyar Katz, Sigal Grisariu, Chava Perry, Ronit Gurion, Batia Avni, Tsila Zuckerman, Irit Avivi Mazza, Ron Ram

Blood (2023) 142 (Supplement 1): 4886.

https://doi.org/10.1182/blood-2023-188473

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Ido Wolf, Odelia Amit, Ronit Yerushalmi, Yakir Moshe, Noga Shem-Tov, Gil Fridberg, Ivetta Danylesko, Irit Avivi Mazza, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2023-182826

Published: 2023

Journal Articles

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Mazyar Shadman, Matthew J Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini

Blood (2023) 142 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2023-180233

Published: 2023

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Odelia Amit, Shai Winer, Yakir Moshe, Pia Raanani, Eitan Kugler, Moshe Yeshurun, Irit Avivi, Ofir Wolach

Blood (2022) 140 (Supplement 1): 10637–10638.

https://doi.org/10.1182/blood-2022-164543

Published: 2022

Journal Articles

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 7509–7511.

https://doi.org/10.1182/blood-2022-169459

Published: 2022

Journal Articles

Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes - a Single Center Longitudinal Cohort Analysis

Gil Fridberg, Odelia Amit, Chen Karni, Dina Tshernichovsy, David Shasha, Vanessa Rouach, David Verssano, Amir Bar-Shai, Gilad Wasserman, Ilan Goldberg, Irit Avivi, Ron Ram

Blood (2022) 140 (Supplement 1): 10557–10558.

https://doi.org/10.1182/blood-2022-163786

Published: 2022

Journal Articles

Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience

Sigal Grisariu Greenzaid, Ron Ram, Mona Kazuli, Dana Yehudai-Ofir, Liat Shargian, Tsila Zuckerman, Moshe Yeshurun, Odelia Amit, Yael Bar-On, Eran Zimran, Adir Shaulov, Polina Stepensky, Jacob Strahilevitz, Batia Avni

Blood (2022) 140 (Supplement 1): 12833–12834.

https://doi.org/10.1182/blood-2022-164694

Published: 2022

Journal Articles

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 6558–6560.

https://doi.org/10.1182/blood-2022-167644

Published: 2022

Journal Articles

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C Pasquini, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 1584–1587.

https://doi.org/10.1182/blood-2022-158822

Published: 2022

Journal Articles

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Blood (2022) 140 (Supplement 1): 3816–3817.

https://doi.org/10.1182/blood-2022-165149

Published: 2022

Journal Articles

Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

Robert Zeiser, Christoph Schmid, Gheath Alatrash, Ron Ram, Yuan Wu, Hans-Jochen Jochen Weber, Stephanie Grzesiak, Lamis K. Eldjerou, Charles Craddock

Blood (2022) 140 (Supplement 1): 8944–8945.

https://doi.org/10.1182/blood-2022-167011

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study

Oren Pasvolsky, Shai Shimony, Ron Ram, Avichai Shimoni, Liat Shargian-Alon, Batia Avni, Ofir Wolach, Tzippy Shochat, Ronit Yerushalmi, Odelia Amit, Pia Raanani, Moshe Yeshurun

Blood (2021) 138 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2021-144772

Published: 2021

Journal Articles

Sequential Therapy with Fitcy Preparative Regimen for Patients with Primary Refractory AML - a Single Center Retrospective Analysis

Odelia Amit, Yakir Moshe, Inna Ospovat, Yael Bar-On, Ofrat Beyar-Katz, Dina Tshernichovsy, Irit Avivi, Ron Ram

Blood (2021) 138 (Supplement 1): 2860.

https://doi.org/10.1182/blood-2021-152699

Published: 2021

Journal Articles

A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

Ron Ram, Sigal Grisariu, Liat Shargian-Alon, Dana Yehudai-Ofir, Irit Avivi, Orit Gutfeld, Polina Stepensky, Tsila Zuckerman, Moshe Yeshurun, Odelia Amit, Batia Avni, Ronit Gurion, Yael Bar-On, Ofrat Beyar-Katz, Ronit Gold, Shimrit Ringelstein, Itai Levi, Tzvi Porges, Chava Perry

Blood (2021) 138 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2021-151085

Published: 2021

Journal Articles

Antibiotic Stewardship in Patients after Cellular Therapy with Febrile Neutropenia- a Single Center Prospective Unblinded Randomized Trial

Ron Ram, Odelia Amit, Amos Adler, Yael Bar-On, Ofrat Beyar-Katz, Irit Avivi, David Shasha, Ronen Ben-Ami

Blood (2021) 138 (Supplement 1): 747.

https://doi.org/10.1182/blood-2021-152559

Published: 2021

NARROW

Determinants of Response to Anti CD-19 CAR-T Cells for Diffuse Large B-Cell Lymphoma in Pre-Treatment Peripheral Blood Mononuclear Cells Using Single-Cell RNA-Seq

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes - a Single Center Longitudinal Cohort Analysis

Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study

Sequential Therapy with Fitcy Preparative Regimen for Patients with Primary Refractory AML - a Single Center Retrospective Analysis

A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

Antibiotic Stewardship in Patients after Cellular Therapy with Febrile Neutropenia- a Single Center Prospective Unblinded Randomized Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only